• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Research in the inhibitory effect of sarcoplasmic reticulum Ca release channel stabilizer on the development of heart failure

Research Project

Project/Area Number 13670717
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Circulatory organs internal medicine
Research InstitutionYamaguchi University

Principal Investigator

YANO Masafumi  Yamaguchi University Hospital, Associate Professor, 医学部附属病院, 講師 (90294628)

Co-Investigator(Kenkyū-buntansha) OHKUSA Tomoko  Yamaguchi University School of Medicine, Assistant Professor, 医学部, 助手 (00294629)
Project Period (FY) 2001 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥4,000,000 (Direct Cost: ¥4,000,000)
Fiscal Year 2002: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2001: ¥2,800,000 (Direct Cost: ¥2,800,000)
Keywordsheart failure / sarcoplasmic reticulum / ryanodine receptor / FK506 binding protein / beta-blocker / Ca放出能
Research Abstract

In heart failure, abnormal function of sarcoplasmic reticulum (SR) is one of the major pathogenic mechanisms in heart failure. Here, we assessed the effects of 1,4-benzothiazepine derivative JTV519 (intracellular Ca2+ modulator) and propranolol on cardiac and SR functions. SR vesicles were isolated from dog LV muscles {normal (N), n=11; 4-weeks rapid RV pacing with or without JTV519 (JT:14.4 mg/Kg/day) or propranolol (PL:0.05mg/kg/day) [untreated: n=10, JT(+): n=10, PL(+): n=10, respectively]}. 1) In either JT(+) or PL(+), cardiac function was improved compared with untreated group. 2) Abnormal SR Ca2+ leak was found in untreated failing SR. A benzothiazepine Ca^<2+> antagonist diltiazem as well as JTV519 acutely inhibited this Ca^<2+> leak in failing SR (IC50= 0.3μM, 0.03μM, respectively), and neither nifedipine nor verapamil affected the Ca^<2+> leak. There was no abnormal SR Ca^<2+> leak either in JT(+) and PL(+). 3) Both JTV519 and propranolol prevented the decrease in the stoichiometry of RyR vs FKBP12.6 assessed by [^3H]ryanodine and [^3H]FK 506-bindng assays [1:3.6 in normal, 1:1.3 in untreated, 1:3.6 in JT(+), 1:2.4 in PL(+)]. 4) In untreated group, RyR was PKA- hyperphosphorylated, whereas it was reversed both in JT(+) and in PL(+). 5) The amount of RyR-bound FKBP12.6 was tremendously less in untreated group than normal RyR, whereas it was reversed both in JT(+) and PL(+). 6) RyR was labeled in a site-directed fashion with the fluorescent conformational probe methylcoumarin acetate (MCA). In both J(+) and P(+), the level of MCA fluorescence, which was higher in untreated group, was decreased back towards normal, suggesting the improvement of RyR conformational state by both treatments. Both JTV519 and proplanolol improved cardiac function and attenuated LV remodeling by ameliorating the defective interaction of FKBP12.6 with RyR through restoration of PKA-hyperphosphorylation of RyR and the following conformational change of RyR.

Report

(3 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report
  • Research Products

    (12 results)

All Other

All Publications (12 results)

  • [Publications] Takayuki Hisaoka: "Enhancement of Rho/Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure"Cardiovascular Research. 49. 319-329 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Masahiro Doi: "Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor"Circulation. 105. 1374-1379 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Masafumi Yano: "FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure"Circulation. 107. 477-484 (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Masateru Kohno: "A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure"American Journal of Physiology. 284. H1035-H1042 (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Hisaoka T., Yano M., Ohkusa T., et al.: "Enhancement of Rho/ Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure"Cardiovasc Res. 49. 319-329 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Doi M., Yano M., Kobayashi S., et al.: "Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor"Circulation. 105. 1374-1379 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Yano M., Kobayashi S., Kohno M., et al.: "FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure"Am J. Phisiol.. 284. H1035-1042 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Kohno M., Yano M., Kobayashi S., et al.: "A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure"Circulation. 107. 477-484 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Masahiro Doi: "Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor"Circulation. 105. 1374-1379 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Masafumi Yano: "FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor)as a novel therapeutic strategy against heart failure"Circulation. 107. 477-484 (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Masateru Kohno: "A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure"American Journal of Physiology. 284. 1035-1042 (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Masahiro Doi: "Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor."Circulation. (in press). (2002)

    • Related Report
      2001 Annual Research Report

URL: 

Published: 2001-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi